Lilly UK patent victory causes concern for biotech patents
This article was originally published in Scrip
A UK court judgement upholding the invalidity of a patent filed by Human Genome Sciences could cast doubt on the legitimacy of other bioinformatics-based patents, lawyers warn.
You may also be interested in...
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in a move towards increasing biosimilar uptake.
EFPIA, the European Federation of Pharmaceutical Industries and Associations, has put forward what it thinks the European regulatory network strategy to 2025 should prioritize.